For the third quarter of the fiscal year ending December 2026, consolidated net sales were 10,467 million yen (up 4.1% year-over-year), while operating income was 509 million yen (-44.2%), ordinary income was 568 million yen (-34.8%), and net income attributable to owners of parent for the quarter was 301 million yen (-54.7%), all decreasing. Own sales increased due to expanded sales of a new urology product. Overseas and OEM results fluctuated due to composition factors. Full-year forecast is unchanged. Attention should be paid to the status of treasury stock acquisitions.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"5187","jir_company_name":"Create Medic Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/5187-20261102-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending December 2026, consolidated net sales were 10,467 million yen (up 4.1% year-over-year), while operating income was 509 million yen (-44.2%), ordinary income was 568 million yen (-34.8%), and net income attributable to owners of parent for the quarter was 301 million yen (-54.7%), all decreasing. Own sales increased due to expanded sales of a new urology product. Overseas and OEM results fluctuated due to composition factors. Full-year forecast is unchanged. Attention should be paid to the status of treasury stock acquisitions.","jir_summary":"### Overview of Results\nCreate Medic Co., Ltd. increased own sales driven by expanded sales of a new urology product; however, operating income, ordinary income and net income decreased year-over-year due to a rise in cost of goods sold as a result of yen depreciation, increased expenses in overseas operations, and higher M&A-related costs. Although net sales rose year-over-year, profitability was pressured, indicating a risk of divergence from the initial forecasts. By segment, own sales performed well, overseas sales were affected by certain factors, and OEM remained strong.\n\n### Financial Position and Outlook\nTotal assets stood at 19,831 million yen, and the equity ratio was 81.4% (slight decrease from the previous fiscal year). Treasury stock acquisitions progressed, and treasury stock amounted to 1,687,151 thousand yen. Financial condition is stable, but the consolidated earnings forecast remains unchanged, and the company will monitor domestic and international business conditions. Earnings presentation materials will be released, and forecasts may be revised and announced if necessary.","jir_financial_highlights":"Net Sales: 10,467 million yen (Up 4.1% Year-over-Year)\nOperating Income: 509 million yen (-44.2% Year-over-Year)\nOrdinary Income: 568 million yen (-34.8% Year-over-Year)\nNet Income Attributable to Owners of Parent (quarter): 301 million yen (-54.7% Year-over-Year)\nNet Assets per Share: 2,028.71 yen (Compared with the end of the previous fiscal year)","jir_category":"","jir_hashtags":"#CreateMedic, #Earnings, #ConsolidatedResults","jir_key_figures":"Net Sales: 10,467 million yen (Up 4.1% Year-over-Year)\nOperating Income: 509 million yen (-44.2% Year-over-Year)\nNet Income Attributable to Owners of Parent (quarter): 301 million yen (-54.7% Year-over-Year)","jir_meta_title":"Create Medic Co., Ltd. \u2014 Q3 FY2026 Financial Summary | Net Sales 10,467 million yen (YoY +4.1%)","jir_meta_description":"Key points of Create Medic Co., Ltd.'s Q3 FY2026 consolidated results: net sales increased while profits declined. Own sales supported by new product contribution. Full-year forecast maintained. See IR materials for details.","jir_og_title":"Create Medic Co., Ltd. Q3 Results: Sales Up, Profits Down","jir_og_description":"In Q3, Create Medic Co., Ltd. reported higher net sales year-over-year, while operating income, ordinary income and net income fell significantly. Outlook and key points explained.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59045,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-140103","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n